Yann  Mazabraud net worth and biography

Yann Mazabraud Biography and Net Worth

Yann Mazabraud joined Rhythm as Executive Vice President, Head of International, in October 2020. Yann brings more than two decades of experience leading rare disease global commercial strategy, market access and marketing. He joined the Company from Trevi Therapeutics, where he served as Chief Commercial Officer and Head of International for two years. Prior to that, he held several leadership positions at Sanofi Genzyme, including, Head of Latin America, U.S. General Manager and North America Head, Rare Diseases. He also served as a member of the Sanofi Genzyme Executive Leadership Team. While at Genzyme and Sanofi Genzyme, he led and managed several product launches for rare genetic diseases in Europe, Latin America and the United States across multiple areas including genetics, pediatrics, nephrology, neurology and endocrinology. Yann holds a master’s degree in management from Ecole Supérieure de Commerce de La Rochelle.

What is Yann Mazabraud's net worth?

The estimated net worth of Yann Mazabraud is at least $1.47 million as of March 19th, 2024. Mr. Mazabraud owns 24,495 shares of Rhythm Pharmaceuticals stock worth more than $1,467,740 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Mazabraud may own. Additionally, Mr. Mazabraud receives an annual salary of $936,910.00 as EVP at Rhythm Pharmaceuticals. Learn More about Yann Mazabraud's net worth.

How old is Yann Mazabraud?

Mr. Mazabraud is currently 51 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who is 70 years old. Learn More on Yann Mazabraud's age.

What is Yann Mazabraud's salary?

As the EVP of Rhythm Pharmaceuticals, Inc., Mr. Mazabraud earns $936,910.00 per year. The highest earning executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who commands a salary of $1,350,000.00 per year. Learn More on Yann Mazabraud's salary.

How do I contact Yann Mazabraud?

The corporate mailing address for Mr. Mazabraud and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Yann Mazabraud's contact information.

Has Yann Mazabraud been buying or selling shares of Rhythm Pharmaceuticals?

Yann Mazabraud has not been actively trading shares of Rhythm Pharmaceuticals in the last ninety days. Most recently, Yann Mazabraud sold 16,000 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $39.22, for a transaction totalling $627,520.00. Following the completion of the sale, the executive vice president now directly owns 24,495 shares of the company's stock, valued at $960,693.90. Learn More on Yann Mazabraud's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 26 times. They sold a total of 410,931 shares worth more than $20,497,452.48. The most recent insider tranaction occured on November, 11th when EVP Jennifer Kayden Lee sold 66,861 shares worth more than $4,434,890.13. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 11/11/2024.

Yann Mazabraud Insider Trading History at Rhythm Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2024Sell16,000$39.22$627,520.0024,495View SEC Filing Icon  
2/12/2024Sell1,594$51.38$81,899.727,702View SEC Filing Icon  
2/15/2022Sell934$6.10$5,697.40View SEC Filing Icon  
See Full Table

Yann Mazabraud Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows Yann Mazabraud's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $59.92
Low: $58.02
High: $60.07

50 Day Range

MA: $52.94
Low: $47.20
High: $67.33

2 Week Range

Now: $59.92
Low: $31.52
High: $68.58

Volume

56,835 shs

Average Volume

546,822 shs

Market Capitalization

$3.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09